Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06171750 · ClinicalTrials.gov registry record · Phase 1

Phase I Study of Tolododekin Alfa (ANK-101) in Advanced Solid Tumors

A Phase 1 study of Non-Small Cell Lung Cancer and Solid Tumor, sponsored by Ankyra Therapeutics.

Recruiting
Registry status
Phase 1
Development phase
97
Enrollment target
5
Study locations

NCT06171750 is a Phase 1 study of Non-Small Cell Lung Cancer and Solid Tumor that is actively recruiting participants, run by Ankyra Therapeutics. The registered enrollment target is 97 participants, below the 659-participant average among 449 other Non-Small Cell Lung Cancer trials with a reported enrollment target (85% lower). The trial reports 5 study locations across 5 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06171750, a Phase 1 study of Non-Small Cell Lung Cancer and Solid Tumor, is actively recruiting participants, sponsored by Ankyra Therapeutics.

RECRUITING
Registry status
Phase 1
Development phase
97 participants
Enrollment target
5
Study locations

Study Summary

This is a Phase 1, multicenter, open-label dose escalation study to determine the safety and tolerability of intratumoral (IT) injection of tolododekin alfa (ANK-101) in participants with advanced solid tumors who have progressed during or after receiving standard of care (SOC) therapy or who will not benefit from such therapy. The study will be conducted in three parts; in Part 1, participants with superficial lesions will receive ANK-101 as a single agent; in Part 2, participants with visceral lesions will receive ANK-101 as a single agent; and in Part 3, participants with cutaneous squamous cell carcinoma (CSCC) will receive ANK-101 in combination with cemiplimab.

Conditions Studied

Non-Small Cell Lung Cancer Solid Tumor Advanced Solid Tumor Metastatic Solid Tumor Cutaneous Squamous Cell Carcinoma Malignant Solid Tumor Cutaneous Tumor Subcutaneous Tumor Metastasis to Soft Tissue

Interventions

  • DRUG Cemiplimab
  • DRUG tolododekin alfa

Study Locations (5)

Maryland

  • National Cancer Institute - Bethesda

Massachusetts

  • Massachusetts General Hospital - Boston

Oregon

  • Providence Cancer Institute - Portland

Pennsylvania

  • Hillman Cancer Center - Pittsburgh

Ontario

  • Princess Margaret Cancer Centre - Toronto

Trial Details

FieldValue
Enrollment Target 97 participants
Start Date 2024-01-19
Est. Completion 2027-06
Phase Phase 1

Sponsor

Ankyra Therapeutics

2 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT06171750

The ClinicalTrials.gov registry entry for NCT06171750 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 97 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 659-participant average among 449 other Non-Small Cell Lung Cancer trials with a reported enrollment target (85% lower). The listed sponsor is Ankyra Therapeutics, which has 2 total studies on file at ClinicalTrials.gov.

The record links to 9 conditions, with Non-Small Cell Lung Cancer appearing as the primary indexed condition, and to 2 interventions - of which Cemiplimab is the first listed.

NCT06171750 reports 5 study locations spanning 5 distinct geographic areas - top geographies include Maryland, Massachusetts, Oregon.

Frequently Asked Questions

What is clinical trial NCT06171750 about?

NCT06171750 is a clinical study titled "Phase I Study of Tolododekin Alfa (ANK-101) in Advanced Solid Tumors". This is a Phase 1, multicenter, open-label dose escalation study to determine the safety and tolerability of intratumoral (IT) injection of tolododekin alfa (ANK-101) in participants with advanced solid tumors who have progressed during or after receiving standard of care (SOC) therapy or who will n...

What is the current status of trial NCT06171750?

This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 97 participants. The study started on 2024-01-19. Estimated completion is 2027-06.

What conditions does trial NCT06171750 study?

This clinical trial studies the following conditions: Non-Small Cell Lung Cancer, Solid Tumor, Advanced Solid Tumor, Metastatic Solid Tumor, Cutaneous Squamous Cell Carcinoma.

What interventions are being tested in trial NCT06171750?

The interventions under investigation include: Cemiplimab (DRUG), tolododekin alfa (DRUG).

Who is sponsoring clinical trial NCT06171750?

This trial is sponsored by Ankyra Therapeutics, which has 2 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06171750 being conducted?

This trial has 5 study locations across Maryland, Massachusetts, Oregon, Pennsylvania, Ontario. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Non-Small Cell Lung Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Non-Small Cell Lung Cancer

All registered trials for this condition

Solid Tumor

All registered trials for this condition

Maryland

All trials with a study site in Maryland

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.